Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 57 people across three groups based on their type of lymphoma (a cancer of the lymph system): 23 with T-Cell Lymphoma (TCL), 19 with Indolent (slow-growing) B-Cell Lymphoma (IBCL), and 15 with Aggressive B-Cell Lymphoma (ABCL). All participants received at least one dose of the study drug. The trial's main goal was to measure how many participants showed a tumour response — meaning their cancer either disappeared completely or shrank significantly according to set medical criteria. The reported data shows that, for the primary measure of tumour response rate, the figure was 0% across most subgroups. The only subgroups where any response was recorded were: participants with a history of slow-growing B-Cell Lymphoma who had converted to an aggressive form (10% response rate), and participants with Cutaneous T-Cell Lymphoma — a type affecting the skin (9.1% response rate). For the secondary measures, the reported data shows how long participants went without their disease getting worse (called progression-free survival). This ranged from a median of 58 days in the Peripheral T-Cell Lymphoma subgroup up to 429 days in the Follicular Grade 1 & 2 subgroup. At the one-year mark, the percentage of participants still alive and without their disease worsening ranged from 0% in some subgroups to around 51% in the Follicular Grade 1 & 2 subgroup. Regarding drug-related unwanted effects, the reported data shows that 2 participants in the T-Cell group, 3 in the Indolent B-Cell group, and 0 in the Aggressive B-Cell group experienced one or more drug-related adverse events, though no further detail on the nature of those events was included in this results data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Lymphoma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have measurable areas of disease that can be tracked (for example, tumors that show up on scans)
- You have recovered from any previous chemotherapy treatments
- Your doctors estimate you have a life expectancy of at least 12 weeks
- Your liver is functioning well enough, based on blood test results showing liver enzyme and bilirubin levels within acceptable ranges (confirm with trial site)
- Your kidneys are functioning well enough, based on a blood test showing creatinine levels within an acceptable range (confirm with trial site)
- Your bone marrow is producing enough blood cells, specifically platelets above a certain level shown in a blood test (confirm with trial site)
Who may not be able to join:
- You have a second, separate cancer (unless it was a non-melanoma skin cancer, or another cancer that has been fully treated and considered cured by surgery or radiation)
- You have received any lymphoma treatment within the past 3 weeks
- You are unable to swallow tablets
- You are currently taking certain seizure medications — specifically carbamazepine, phenobarbital, or phenytoin — and are unable to stop taking them at least 14 days before joining the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR])
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.